Literature DB >> 27894510

Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting.

Dan Călugăru1, Mihai Călugăru1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27894510     DOI： 10.1016/j.ajo.2016.10.013

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  4 in total

1.  Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-07       Impact factor: 3.117

2.  Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-09       Impact factor: 3.117

3.  Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-20       Impact factor: 3.117

4.  Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study).

Authors:  Elisabeth Van Aken; Mérédis Favreau; Eva Ramboer; Kris Denhaerynck; Karen MacDonald; Ivo Abraham; Heidi Brié
Journal:  Clin Ophthalmol       Date:  2020-12-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.